Business Model TG Therapeutics generates revenue primarily through the sale of BRIUMVI in the U.S. and through licensing and milestone payments from its partner, Neuraxpharm, for commercialization outside of the U.S. Revenue Sources * BRIUMVI U.S. net product sales * License, milestone, royalty, and other revenue from Neuraxpharm Income
Business Model Novartis generates revenue from the sale of innovative medicines across four core therapeutic areas: Cardiovascular-Renal-Metabolic, Immunology, Neuroscience, and Oncology. Revenue growth is driven by key brands and new product launches. Revenue Sources * Entresto: A key growth driver with robust demand in the US and Europe, indicated for heart
Business Model Novavax generates revenue primarily through product sales, licensing, royalties, grants, and other collaborative agreements related to its vaccine technology platform. Revenue Sources * Product sales of Nuvaxovid COVID-19 vaccine in various global markets. * Licensing, royalties, and other revenue from partnerships, including the Sanofi CLA. * Grants from governmental and non-governmental
Business Model ADMA Biologics generates revenue primarily through the manufacturing and marketing of specialty biologics, specifically plasma-derived products for the treatment of immune deficiencies and prevention of certain infectious diseases. Revenue Sources * ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI). * BIVIGAM® (immune
Business Model Surgery Partners generates revenue primarily through its network of surgical facilities, including ambulatory surgery centers and surgical hospitals, by providing surgical and related ancillary care services. The company focuses on high-quality, cost-effective solutions for patients and physicians. Revenue Sources * Surgical procedures performed at ambulatory surgery centers (ASCs). * Surgical
Business Model Solventum generates revenue through the sale of products, software, and rentals across its four business segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. Revenue Sources * Net sales of product: $6,348 million (Year ended December 31, 2024) * Net sales of software and rentals: $1,906
Business Model Teleflex generates revenue through the sale of medical technologies across various segments. Revenue Sources * Americas segment: Includes sales in the United States and other countries in the Americas. * EMEA segment: Includes sales in Europe, the Middle East, and Africa. * Asia segment: Includes sales in the Asia Pacific region.
Business Model Universal Health Services generates revenue primarily from owning and operating acute care hospitals and behavioral health care facilities. Revenue is derived from patient services, including general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic care, coronary care, pediatric services, pharmacy services and/or behavioral
Business Model Medical Properties Trust (MPT) generates revenue primarily by leasing hospital facilities to operating companies under long-term net leases. They also derive income from financing leases, mortgage loans, and investments in unconsolidated real estate joint ventures and operating entities. Revenue Sources * Rent billed from hospital facilities (General acute care,
Business Model The GEO Group generates revenue through contracted support services for secure facilities, processing centers, reentry centers, enhanced in-custody rehabilitation, post-release support, electronic monitoring programs, secure transportation, community-based programs, and correctional health and mental health care. Revenue Sources * Secure Services (Owned and Leased): Primarily from contracts with government agencies
Business Model Privia Health generates revenue from three primary sources: (i) Fee-for-Service (FFS) patient care revenue, (ii) Value-Based Care (VBC) revenue, and (iii) other revenue from additional services. Revenue Sources * FFS-patient care revenue: Generated from healthcare services provided by Privia Providers in Owned and Friendly Medical Groups. * FFS-administrative services revenue:
Business Model Viatris operates as a global healthcare company that bridges the traditional divide between generics and brands. Revenue Sources * Brands: Sales of brand-name drugs such as Lipitor, Norvasc, Lyrica, Creon, and Viagra * Generics: Sales of generic drugs. The Generics portfolio includes core generics and complex generics Income Statement Analysis
Business Model Iovance generates revenue primarily through sales of Amtagvi and Proleukin. Revenue Sources * Amtagvi: Revenue is recognized upon patient infusion. Amtagvi is the first FDA-approved T cell therapy for a solid tumor indication, specifically advanced melanoma after anti-PD-1 and targeted therapy. * Proleukin: Used in the Amtagvi treatment regimen and
Business Model TransMedics generates revenue primarily through the utilization of its Organ Care System (OCS) across lung, heart, and liver transplants via the National OCS Program (NOP), as well as from TransMedics logistics services. Revenue Sources * Net product revenue from the sale of OCS devices. * Service revenue from the National
Business Model Clover Health generates revenue primarily through premiums earned from its Medicare Advantage plans, with a focus on PPO and HMO plans. They also generate revenue through other income. Revenue Sources * Premiums earned, net (primarily from Medicare Advantage plans) * Other income Income Statement Analysis * Premiums earned, net increased by
Business Model Lantheus generates revenue from radiopharmaceutical oncology (primarily PYLARIFY), precision diagnostics (DEFINITY and TechneLite), and strategic partnerships. Revenue Sources * PYLARIFY: PSMA PET imaging agent for prostate cancer. * DEFINITY: Ultrasound enhancing agent. * TechneLite: Component in radiopharmaceuticals. * Strategic partnerships: Sales of MK-6240 for investigational use. Income Statement Analysis * Revenue increased 10.
Business Model Madrigal Pharmaceuticals generates revenue primarily through net product sales of Rezdiffra. Revenue Sources * Net product revenue from Rezdiffra sales. Income Statement Analysis * Product revenue, net, significantly increased due to the commercial launch of Rezdiffra in April 2024. * Research and development expenses decreased primarily due to a reduction in
Business Model Beyond Meat generates revenue through the sale of plant-based meat products across various channels including retail and foodservice, both in the U.S. and internationally. Revenue Sources * Sales of plant-based meat alternatives to retail consumers. * Partnerships with foodservice providers (restaurants, QSRs) to offer Beyond Meat products on their
Business Model Teladoc Health generates revenue through access fees and other revenue. Access fees are derived from contracts providing access to their virtual care platform, while other revenue includes visit fees and other related services. Revenue Sources * Access fees revenue: $543.1 million in Q4 2024, decreased 5% year-over-year. * Other
Business Model Merit Medical generates revenue through the sale of medical devices used in interventional, diagnostic, and therapeutic procedures, mainly in cardiology, radiology, oncology, critical care, and endoscopy. They offer a diverse range of products and custom procedural solutions. Revenue Sources * Cardiovascular segment: Peripheral Intervention, Cardiac Intervention, Custom Procedural Solutions,
Business Model Elanco generates revenue from two primary segments: Pet Health and Farm Animal. Pet Health includes products for companion animals, while Farm Animal includes products for livestock. Revenue Sources * Pet Health: Parasiticides (e.g., Advantage Family, Seresto, AdTab, Credelio Quattro), dermatology products (e.g., Zenrelia), vaccines, and pain management.
Business Model Henry Schein, Inc. generates revenue through the sale of dental and medical products and services to office-based dental and medical practitioners, dental laboratories, government and institutional health care clinics, and other alternate care sites. The company operates through three segments: Global Distribution and Value-Added Services, Global Specialty Products,
Business Model Myriad Genetics generates revenue primarily through molecular diagnostic testing and precision medicine, offering tests that assess disease risk, progression, and guide treatment decisions. Revenue Sources * Hereditary Cancer Testing: MyRisk, BRACAnalysis CDx * Tumor Profiling: myChoice CDx, Prolaris, Precise Tumor, EndoPredict * Prenatal Testing: Foresight, Prequel, SneakPeek * Pharmacogenomics: GeneSight Income Statement
Business Model BioCryst generates revenue primarily through sales of ORLADEYO for hereditary angioedema (HAE) and RAPIVAB for influenza. The majority of revenue comes from ORLADEYO. Revenue Sources * ORLADEYO net revenue: $124.2 million for Q4 2024 and $437.7 million for FY 2024 * RAPIVAB net revenue: $7.3 million for
Business Model Veracyte generates revenue through testing services (Decipher, Afirma), product sales (Prosigna), and biopharmaceutical collaborations. Revenue Sources * Testing revenue: Primarily from Decipher and Afirma genomic tests. * Product revenue: From sales of Prosigna. * Biopharmaceutical and other revenue: Collaborations with biopharmaceutical companies. Income Statement Analysis * Total revenue increased by 21% due
Business Model Tempus AI generates revenue primarily through Genomics (diagnostic testing) and Data (licensing & analytical tools) with a growing contribution from Applications (therapy/trial matching & algorithmic diagnostics). Revenue Sources * Genomics: Diagnostic testing services provide revenue from running tests and billing insurance or direct payment. * Data: Licensing de-identified multimodal
Business Model Summit Therapeutics is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Currently, their primary focus is on the development of
Business Model Balchem Corporation generates revenue through the development, manufacture, distribution, and marketing of specialty performance ingredients and products across three main segments: Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products (SP). Revenue Sources * Human Nutrition and Health (HNH): Provides human-grade choline nutrients, mineral amino
Business Model Insulet generates revenue primarily through the sale of its Omnipod Insulin Management System, including Omnipod 5, and through drug delivery services. Revenue Sources * Omnipod Insulin Management System sales, including disposable Pods. * Drug delivery services to partners. Income Statement Analysis * Revenue increased by 17.2% year-over-year, driven by growth
Business Model Baxter generates revenue through a diverse portfolio of diagnostic, critical care, nutrition, hospital, and surgical products, sold across various sites of care including patient homes, hospitals, physician offices, and other healthcare facilities. Revenue Sources * Medical Products & Therapies: Includes sterile IV solutions, infusion systems, parenteral nutrition therapies, and
Business Model Exact Sciences Corporation generates revenue primarily through sales of cancer screening tests, including Cologuard, and precision oncology tests, such as Oncotype DX. Revenue Sources * Screening revenue from Cologuard tests and PreventionGenetics * Precision Oncology revenue from global Oncotype DX and therapy selection tests Revenue Distribution by Channel * Revenue generated
Business Model Garmin generates revenue through the sale of navigation, communication, and information devices and applications that are enabled by GPS technology across five business segments: Fitness, Outdoor, Aviation, Marine, and Auto OEM. Revenue Sources * Fitness segment: sales of wearables and fitness devices, including smartwatches and cycling computers * Outdoor segment:
Business Model IFF generates revenue primarily through its four main business segments: Nourish, Health & Biosciences, Scent, and Pharma Solutions. Revenue Sources * Nourish segment, including Flavors and Functional Ingredients * Health & Biosciences segment, including Cultures & Food Enzymes, Home & Personal Care, Grain Processing, and Animal Nutrition * Scent segment, including
Business Model Halozyme generates revenue through royalties from partners' products utilizing their ENHANZE technology, product sales from their proprietary products, and collaborative agreements including milestone payments. Revenue Sources * Royalties from partners' sales of products using ENHANZE technology. * Product sales of proprietary products such as XYOSTED and Hylenex. * Revenues
Business Model Penumbra generates revenue primarily through the sale of innovative medical devices for the treatment of vascular conditions, including thrombectomy devices and embolization and access products. Revenue Sources * Thrombectomy product sales * Embolization and access product sales Income Statement Analysis * Adjusted revenue increased by 12.9% year-over-year due to strong
Business Model Medtronic generates revenue primarily through sales of medical devices and therapies across its four main business segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Revenue Sources * Cardiovascular Portfolio, including Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, Coronary & Peripheral Vascular * Neuroscience Portfolio, including Cranial & Spinal Technologies,
Business Model GE HealthCare generates revenue primarily through the sale of medical equipment, pharmaceutical diagnostics, and associated services across four main segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Revenue Sources * Sales of Imaging equipment such as MRI, CT scanners, and X-ray systems. * Sales
Business Model Moderna generates revenue primarily through the sale of its mRNA-based vaccines, including Spikevax (COVID-19 vaccine) and mRESVIA (RSV vaccine). Revenue also includes grant, collaboration, licensing, and royalty revenue. Revenue Sources * Spikevax (COVID-19 vaccine) sales * mRESVIA (RSV vaccine) sales * Grant, collaboration, licensing, and royalty revenue Income Statement Analysis * Total
Business Model Zoetis generates revenue through a diverse portfolio of animal health products, including medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions. Revenue Sources * Companion Animal Products (approximately 68% of 2024 revenue): Parasiticides, vaccines, dermatology products, anti-infectives, pain and sedation medications, diagnostics. * Livestock Products
Business Model Organon generates revenue primarily through sales of women's health products, biosimilars, and established brands across various therapeutic areas. Revenue Sources * Women's Health products, including contraceptives like Nexplanon and fertility treatments. * Biosimilars, including products like Renflexis, Ontruzant, and Hadlima. * Established Brands across various therapeutic areas.
Business Model West Pharmaceutical Services, Inc. generates revenue primarily through its two segments: Proprietary Products and Contract-Manufactured Products. The company provides innovative solutions for injectable drug administration and medical devices. Revenue Sources * Proprietary Products segment - includes high-value packaging components and delivery systems such as self-injection devices, NovaPure® components, Westar®
Business Model DexCom, Inc. generates revenue primarily through the sale of continuous glucose monitoring (CGM) systems and related components. Their product offerings include the G Series (G6 and G7 systems), Dexcom ONE+, and the over-the-counter product Stelo. Revenue sources are driven by sensor sales, hardware components like transmitters and receivers,
Business Model DaVita generates revenue primarily through its U.S. dialysis business, providing kidney dialysis services for patients with ESKD. Additional revenue is generated from U.S. integrated kidney care (IKC) business, U.S. other ancillary services (clinical research, transplant software, venture group), and international dialysis operations. Revenue Sources * U.
Business Model CVS Health generates revenue through its four segments: Health Care Benefits (premiums, services, net investment income), Health Services (pharmacy benefit management solutions, health care services), Pharmacy & Consumer Wellness (prescription dispensing, retail sales), and Corporate/Other (management and administrative services). Revenue Sources * Health Care Benefits: Premiums from insured
Business Model Arch Capital Group generates revenue through insurance, reinsurance, and mortgage insurance on a worldwide basis. Revenue Sources * Insurance premiums written from a variety of specialty insurance lines. * Reinsurance premiums written from property, casualty, and specialty lines. * Mortgage insurance premiums written primarily in the U.S. Income Statement Analysis
Business Model Cincinnati Financial Corporation generates revenue primarily through property casualty insurance premiums, life insurance premiums, and investment income. Revenue Sources * Property casualty insurance premiums: Earned premiums from commercial lines, personal lines, and excess & surplus lines. * Life insurance premiums: Earned premiums from term life, whole life, and universal life
Business Model Ecolab generates revenue through sales of products, equipment, services, and leases in the water, hygiene, and infection prevention markets. Revenue Sources * Product and equipment sales: $3,158.0 million in Q4 2024. * Service and lease sales: $847.2 million in Q4 2024. Income Statement Analysis * Net sales increased
Business Model DuPont generates revenue through technology-based materials and solutions across various industries, including electronics, transportation, construction, water, healthcare, and worker safety. Revenue Sources * Electronics & Industrial: Sales driven by semiconductor technologies, interconnect solutions, and industrial solutions. * Water & Protection: Sales from safety solutions, shelter solutions, and water solutions. * Corporate
Business Model Edwards Lifesciences generates revenue through the sale of its structural heart innovations including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart products. Revenue Sources * TAVR sales, including SAPIEN 3 Ultra RESILIA platform * TMTT sales, including PASCAL repair system and EVOQUE tricuspid
Business Model Humana generates revenue primarily through premiums from its insurance products, including Medicare Advantage, state-based contracts, and specialty benefits. It also earns revenue from services within its CenterWell segment, encompassing pharmacy, primary care, and home solutions. Revenue Sources * Premiums from Individual Medicare Advantage, Group Medicare Advantage, Medicare stand-alone PDP,
Business Model Leidos generates revenue through providing services and solutions to government and commercial customers, focusing on digital, mission, and health innovations. Revenue Sources * National Security & Digital solutions * Health & Civil services * Commercial & International services * Defense Systems Income Statement Analysis * Revenues increased by 9.7% year-over-year, indicating strong
Business Model Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Revenue Sources * Revenue is generated from providing clinical development services. Income Statement Analysis * Revenue increased by 7.7% year-over-year, driven by growth in
Business Model Quipt Home Medical Corp. is a premier provider of clinical respiratory care in the home setting throughout the U.S.A. They generate revenue through a diversified product mix, with a focus on respiratory-related products and services. Revenue Sources * Rentals of medical equipment * Sales of respiratory resupplies * Home
Business Model Gilead Sciences generates revenue from the sale of pharmaceutical products, primarily in the areas of HIV, Liver Disease, Oncology, and Other therapeutic areas, along with royalty, contract and other revenues. Revenue Sources * HIV Product Sales: Driven by Biktarvy and Descovy. * Liver Disease Portfolio: Including products for HBV, HDV,
Business Model Royalty Pharma generates revenue primarily through royalty payments on sales of biopharmaceutical products. These royalties are acquired either directly on approved products or through funding development-stage therapies in exchange for future royalties. Revenue Sources * Royalty Receipts: Variable payments based on sales of products (e.g., cystic fibrosis franchise,
Business Model Exelixis generates revenue primarily through the sales of its cabozantinib franchise, including CABOMETYX and COMETRIQ, and through collaboration agreements with partners like Ipsen and Takeda for royalties on cabozantinib sales outside the U.S. Revenue Sources * CABOMETYX net product revenues in the U.S. * COMETRIQ net product revenues
Business Model Vertex Pharmaceuticals generates revenue primarily through the sale of its marketed products, including treatments for cystic fibrosis (CF), sickle cell disease (SCD), transfusion-dependent beta thalassemia (TDT), and acute pain. The main source of revenue is TRIKAFTA/KAFTRIO. Revenue Sources * TRIKAFTA/KAFTRIO: Dominant revenue driver, used for cystic fibrosis
Business Model Roivant generates revenue primarily through collaborations, licensing agreements, and product sales from its various Vant subsidiaries. Revenue Sources * Revenue, net was $9.0 million for the three months ended December 31, 2024. * Revenue, net was $21.5 million for the nine months ended December 31, 2024. Income Statement
Business Model Inspire Medical Systems generates revenue primarily through the sale of its Inspire therapy for obstructive sleep apnea. The therapy includes a neurostimulator, stimulation lead, and sensing lead. Revenue Sources * Sales of Inspire therapy systems to medical centers and hospitals. * Revenue is also generated from international markets. Income Statement
Business Model Arrowhead Pharmaceuticals generates revenue through licensing and collaboration agreements with pharmaceutical companies. Key programs include plozasiran, zodasiran, and olpasiran. Revenue Sources * Upfront payments, milestone payments, and royalties on commercial sales from partnered programs. * Co-development and co-commercialization agreements, primarily within the United States, where profits are shared on a
Business Model Edgewell Personal Care generates revenue through the sale of shaving systems and disposables, shave preparations, feminine care products, sun and skin care products, and wet wipes. Revenue Sources * Wet Shave (Men's Systems, Women's Systems, Disposables, and Shave Preps) * Sun and Skin Care (Sun Care,
Business Model Hain Celestial Group generates revenue through the sale of better-for-you brands across snacks, baby/kids, beverages, meal preparation, and personal care categories. They operate under two reportable segments: North America and International. Revenue Sources * Snacks: Garden Veggie Snacks™, Terra® chips, Garden of Eatin'® snacks, Hartley’s® Jelly
Business Model PetMed Express generates revenue through online sales of pet medications (prescription and non-prescription), pet food, supplements, and supplies, marketed directly to consumers via their websites PetMeds.com and PetCareRx.com, customer contact center, and mobile application. Revenue Sources * Reorder sales (85.1% of Q3 2025 revenue) * New order
Business Model Beyond Air generates revenue through leases of LungFit PH devices to hospitals and medical facilities, as well as consumables (filters, calibration gas, bagging kits, cables, adapters) and services (maintenance, training, back-up). Revenue Sources * Fixed fee arrangements for LungFit PH device leases * Sales of consumables required to use the
Business Model Fortive operates through three segments: Intelligent Operating Solutions (IOS), Precision Technologies (PT), and Advanced Healthcare Solutions (AHS). Revenue is generated from the sale of professional and engineered products, software, and services within these segments. Revenue Sources * Intelligent Operating Solutions: Provides safety and productivity solutions. * Precision Technologies: Offers precision
Business Model Avantor generates revenue primarily through sales of mission-critical products and services to customers in the life sciences and advanced technology industries. The company operates through two segments: Laboratory Solutions and Bioscience Production. Revenue Sources * Laboratory Solutions: Includes a broad range of products and services used in research, development,
Business Model Green Plains generates revenue primarily through the production and sale of ethanol, distillers grains, ultra-high protein products, and renewable corn oil. The company also generates revenue through agribusiness and energy services, including grain handling and storage, commodity marketing, and merchant trading. Revenue Sources * Ethanol production and sales * Sales
Business Model Canopy Growth generates revenue through the production, distribution, and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes. Key revenue streams include Canada cannabis, international markets cannabis, and Storz & Bickel vaporizers. Revenue Sources * Canada cannabis (adult-use and medical) * International markets
Business Model Iterum Therapeutics is focused on delivering differentiated anti-infectives. Their primary revenue driver is expected to be sales of ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs). Revenue Sources * ORLYNVAH™ sales for uUTI treatment in adult women with limited or no alternative oral antibacterial treatment
Business Model Molina Healthcare generates revenue primarily through premiums from managed healthcare services under Medicaid and Medicare programs and through state insurance marketplaces. Revenue Sources * Premium revenue from Medicaid, Medicare, and Marketplace plans. * Premium tax revenue. * Investment income. * Other revenue. Income Statement Analysis * Premium revenue increased by 19.39% in
Business Model Illumina generates revenue through the sale of DNA sequencing and array-based technologies, serving customers in research, clinical, and applied markets. Revenue Sources * Product revenue: Includes sales of instruments and consumables (e.g., flow cells, reagents). * Service and other revenue: Includes instrument service contracts, revenue from CDx agreements, informatics
Business Model AstraZeneca generates revenue through sales of prescription medicines across various therapy areas, including Oncology, Biopharmaceuticals (Cardiovascular, Renal & Metabolism, and Respiratory & Immunology), and Rare Disease. Revenue also includes Alliance Revenue from partnered medicines and Collaboration Revenue from milestones and upfront payments. Revenue Sources * Product Sales: Sales from
Business Model Labcorp generates revenue through its two main segments: Diagnostics Laboratories and Biopharma Laboratory Services. Revenue Sources * Diagnostics Laboratories: Revenue from a broad range of routine and esoteric testing services provided to physicians, hospitals, and other clinical laboratories. * Biopharma Laboratory Services: Revenue from central laboratory services and early development
